Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients

J Neuroimmunol. 2011 Aug 15;237(1-2):66-72. doi: 10.1016/j.jneuroim.2011.06.005. Epub 2011 Jul 6.

Abstract

We determined the T-cell responses against botulinum neurotoxin type A (BoNT/A) and tetanus toxin (TeNT) of peripheral blood lymphocytes from 95 BoNT-treated patients and 63 non-treated control subjects. The patient group included 80 cervical dystonia and 15 other movement disorder cases. Positive T-cell responses to BoNT/A were detected in 70% of the treated patients, and in only 3% of controls. T-cell responses of BoNT-treated patients against BoNT/A did not differ between patients who were clinically responsive and those who had become non-responsive to the treatment. BoNT-treated patients gave significantly higher in vitro T-cell responses to TeNT than did the controls.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Botulinum Toxins, Type A / pharmacology*
  • Botulinum Toxins, Type A / therapeutic use
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Dose-Response Relationship, Immunologic
  • Female
  • Humans
  • In Vitro Techniques
  • Male
  • Middle Aged
  • Movement Disorders / drug therapy
  • Movement Disorders / immunology*
  • Movement Disorders / pathology
  • Neurotoxins / pharmacology*
  • Neurotoxins / therapeutic use
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology*
  • Tetanus Toxin / pharmacology
  • Tetanus Toxin / therapeutic use
  • Young Adult

Substances

  • Neurotoxins
  • Tetanus Toxin
  • Botulinum Toxins, Type A